Latest news
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise? - Yahoo Finance SingaporeYahoo Finance Singapore · Sat, 08 Aug 2026 16:12:05 GMTGUIDANCE: (DOCS) Doximity Expects Fiscal Q2 Revenue Range $170M - $171M, Vs. FactSet Est of $171.8M - MoomooMoomoo · Thu, 06 Aug 2026 21:27:58 GMTAVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven - Investing News NetworkInvesting News Network · Thu, 06 Aug 2026 21:22:13 GMTGUIDANCE: (AMRZ) Amrize Expects 2026 Revenue Range $12.5B-$12.7B, Vs. FactSet Est of $12.45B - MoomooMoomoo · Thu, 06 Aug 2026 21:05:38 GMTICF Reports Second Quarter 2026 Results - ICFICF · Thu, 06 Aug 2026 21:05:21 GMTGUIDANCE: (ESE) ESCO Technologies Now Expects Fiscal 2026 Revenue Range $1.30B-$1.33B, Vs. FactSet Est of $1.32B - MoomooMoomoo · Thu, 06 Aug 2026 20:53:21 GMTGUIDANCE: (SARO) StandardAero Now Expects Full Year 2026 Revenue Range $6.38B - $6.50B, Vs. FactSet Est of $6.43B - MoomooMoomoo · Thu, 06 Aug 2026 20:50:05 GMTGUIDANCE: (QNST) QuinStreet, Inc. Expects Q1 Revenue Range $370.0M - $380.0M - MoomooMoomoo · Thu, 06 Aug 2026 20:47:07 GMT